
Woters[™]

ELSD Performance on Polysorbate Quantification in Infliximab Drug Products

Duanduan Han, Robert Birdsall, Jennifer Simeone, Michael Fogwill, Ying Qing Yu Waters Corporation, Milford, MA




Due to its biocompatibility and low toxicity, polysorbate (PS) is a common excipient for drug products. To ensure PScontaining drug products are safe to administer and quantification of PS is desired. However, as a non-UV active excipient (Figure 1) present at ppm levels in a biological matrix, novel approaches are required in the isolation, detection, and quantitation of polysorbate.


INTRODUCTION

Figure 2. A mixed-mode chromatographic column (Oasis™ Max, 30 µm, 2.1 × 20 mm column) was employed in a trap-and-elute configuration using Waters advance column manager (CM-A) to control a 2-position 6-port valve. Under acidic conditions (H_2O , 2% formic acid) the positively charged protein is passed to waste (value position 1), while the PS is retained on the column. The valve is then switched to position 2, and the PS is eluted to the ELSD (Gain: 100, Power: 75%, Temp.: 80°C, Gas: 20 psi) using organic solvent (IPA, 2% formic acid).

METHODS

| RESULTS | | | | | Polysorbate 80 Results (baseline subtracted) | | | | | |
|---------|-----------------|------------------------------|--|---------------------|--|-------------------------|-------|-------------------------|-------|--|
| | | | | | Exported | ELSD | | CAD | | |
| | Water blank | Water blank 0.1 μg mass load | | Sample | Expected (mg/mL) | Experimental (mg/mL) | RSD | Experimental (mg/mL) | RSD | |
| | 4 gradient ELSD | <mark>ر 100 4 م</mark> | | Remicade™ sample | 0.05 | 0.045 | 1.44% | 0.029 | 3.63% | |





| Avsola™ sample | 0.05 | 0.045 | 2.48% | 0.040 | 6.64% |
|----------------------------------|---------------|-----------------------|-------|-------|--------|
| Inflectra™ sample | 0.05 | 0.044 | 1.04% | 0.047 | 5.13% |
| Renflexis™ sample | 0.05 | 0.042 | 1.48% | 0.038 | 10.87% |
| 7.5 - 6.5 - 6.5 - 5.5 - | • PS X Inf | 80 liximab samples | | | |




Figure 5. Using the baseline subtraction method, concentration of PS was determined in 4 Infliximab drug products. The proposed method was demonstrated to have better accuracy and reproducibility when compared to detectors such as charged aerosol detector (CAD).

subtraction

6.71

6.54

6.36

6.07

5.40

4.16

4.94

4.64

4.00

RSD

0.08%

0.09%

0.02%

0.04%

0.23%

0.14%

0.07%

0.29%

1.02%






Figure 4. When using baseline subtraction, the dynamic range is extended from one order (0.1-1 mg/mL) to two orders (0.01-1 mg/mL) allowing for detection and accurate quantitation of PS using a pre-defined processing method within the Empower[™] 3 Software.

- ELSD can quantify intact polysorbate at formulation levels for biopharmaceuticals
- Baseline subtraction improves LOD for intact polysorbate analysis with ELSD
- Empower 3 Software provides an easy-to-use compliant-ready data processing solution for ELSD
- ELSD provides comparable performance to CAD in polysorbate analysis

References

- Han, D. et al. Comparing ELSD and CAD Performance on Polysorbate Quantification in Infliximab Drug Products, Waters Application Note, 2022. 720007501EN
- McCarthy, S. Quantification of Polysorbate Using the ACQUITY UPLC H-Class Bio System with ELS Detection, Waters Application Note, 2015. 720005323EN

Waters, Oasis, ACQUITY, UPLC, and Empower are trademarks of Waters Technologies Corporation. Remicade is a trademark of Amgen Inc. Inflectra is a trademark of Pfizer Limited. Renflexis is a trademark of N.V. Organon.

TO DOWNLOAD A COPY OF THIS POSTER. VISIT WWW.WATERS.COM/POSTERS